A Young Hematologist’s Take on ICML 2025

1. ICML 2025 reviewed key advancements in lymphoma treatment. 2. Introduction of chemotherapy-free options like R-squared. 3. DLBclass molecular classifier revealed five clusters in DLBCL. 4. Trials showed improved outcomes versus rituximab plus GemOx. 5. Significant response rates in new bispecific and antibody-drug conjugate therapies.